Clin. Exp. Immunol. 1999 — Article demonstrates that beta glucan’s CR3 binding properties can be effective against cancer tumor cells that do not have CR3 receptor sites by potentiating natural killer (NK) cells to see the tumor cells as non-self.  Read more…